Ann: Novogen Announces Outcome of Comprehensive Science Review, page-62

Cevatt
'' we have never been told exactly why GK left and did you noyice a lot of posters pumping the stock left HC at the same time? It could not be a coincidence could it? I mean one of the posters stated he had conversations with GK, others of these posters seemed to claim a personal knowledge of the man and the company''

NRT has had over $199m of contributed equity( cash) since it initial listing over 20 years ago for research and development.

The continuous flow of announcements, updates, forward projections, estimations, partnerships interviews, blogs, emails earlier this year really did excite the market initially and a CR at 30c was completed

Now a few months on - the share price is well over 50% down and NRT has no CEO, CMO, and there is so much uncertainty as to when or if human trials will commence

IMO, The huge potential for Cash burn is why in my opinion the price is not reflecting the value of their technology portfolio

$40m is not a lot of funds especially when a company is yet to complete toxicology programs or even receive approval for any human clinical trials.
Even management has clearly stated several times that $40m will see them through the next 24 months at best and the market is forward looking as to what will occur when the cash is finally exhausted as human trials can take on average many years alone to complete..

DYOR